Biocon gets India marketing rights for Roche’s cancer drug clone: Report

25 Nov 2013 Evaluate

Biocon, Asia’s leading biotechnology enterprise, has reportedly received India marketing rights for Roche’s cancer drug clone. The cancer drug has market of around $6 billion globally. Moreover, the company is likely to market Roche’s cancer drug clone by end of FY14.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.

Biocon Share Price

391.75 1.50 (0.38%)
30-Dec-2025 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.70
Dr. Reddys Lab 1267.20
Cipla 1486.15
Zydus Lifesciences 902.00
Lupin 2086.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×